Bangalore, India: Homes ToLife Unveils Its First Store of Bangalore, India, elevating Home Furniture Shopping to New Heights. With its selection, this specific location, one ofBangalore’s premium shopping destinations, draws an impressive crowd.Homes ToLife, the acclaimed Singapore-based premium furniture brand, is thrilled toannounce the grand opening of its first store in Bangalore, India, nestled in the eleganta Mantri Mall.
This milestone marks the brand’s significant step in actively growing its franchise network throughout India, bringing its renowned furniture offerings and exceptional customer service closer to discerning homeowners across the country.HomesToLife takes immense pride in becoming an integral part of the vibrant city of Bangalore, a place where tradition and modernity blend seamlessly.As the city grows ever larger, HomesToLife is dedicated to providing Bangalore’s residents with exquisite furniture pieces that reflect their unique personalities and enrich their living spaces.
Our leathers come in natural and family-friendly varieties with over 17 leather and fabric variations to suit their diverse lifestyle requirements. One of Homes To Life’s distinguishing features is its transparent pricing policy, ensuring thatall showrooms, including the new Bangalore store, offer the same prices across the board.
On the launch of the store: “The opening of our store in Bangalore is a significant milestone for HomesToLife.We are thrilled to bring our exceptional products and services to the esteemed residents of this stunning city. Our core objective has consistently revolved around improving the quality of life for homeowners, and we believe that the residents of Bangalore will warmly welcome our thoughtfully designed furniture, which radiates sophistication and allure,” stated Celeste Phua, the Global Brand Head of HomesToLife.
HomesToLife’s new store at Mantri Mall, Bangalore, welcomes visitors into an opulentshopping space where they can explore a diverse range of sofas, dining sets, beds, anddecorative accents.
Varun Kant, Country Head India HomesToLife quoted,“With a commitment to providing top-notch, affordably priced furniture, HomesToLifeis rapidly expanding its presence in India. Embracing the motto “Make in India forIndia,” we stand as one of the world’s leading sofa manufacturers, offering the latestglobal styles and a 10-year quality assurance”
For more information about Homes ToLife and its exceptional range of furniture, please visit
~In lieu of Breast Cancer Awareness Month in October, this pioneering initiative signifies Apollo Cancer Centres dedication to women’s health and the fight against breast cancer~
Bangalore, 31st October 2023: Apollo Cancer Centres (ACCs) continues to push the boundaries with advanced cancer treatment, by introducing Indias Fastest & Most Precise Breast Cancer Diagnosis Program’. This pioneering initiative aims to provide swift and precise breast cancer diagnoses, reinforcing the significance of early detection in mitigating the right treatment for a better survival rate, and enhancing the quality of life for patients. This groundbreaking initiative marks a significant stride toward breast cancer management and offers a promising glimpse into the future of healthcare services. Apollo Cancer Centres is proud to be the first in India to provide this program and envisions the potential to replicate the model for other organs in the future. In alignment with Breast Cancer Awareness Month in October, Apollo Cancer Centres is dedicating this program to the timely diagnosis of breast cancer in women. Breast cancer is a prevailing concern for women’s health, and timely diagnosis is the cornerstone of effective intervention. Early detection is paramount in the fight against breast cancer, and we at Apollo Cancer Centre, have achieved a great level of success in treating breast cancer diagnosed in the early stages. We have accomplished breast conservation rates up to 60%, and are able to de-escalate therapy as per global evidence-based guidelines, hence offering our patients superior quality of life outcomes.
Indias Fastest & Most Precise Breast Cancer Diagnosis Program’ is designed to ensure timely and accurate diagnosis, alleviating the stress of protracted waiting times for results. Apollo Cancer Centres firmly believes in the adage, “Earliest Easiest,” when it comes to breast cancer management. This program includes advanced diagnostic technologies, including mammography, ultrasound, and biopsy, to promptly and precisely assess breast health. Patients can expect results within 24 hours, a testament to the program’s efficiency. It is open to individuals seeking breast cancer screening or diagnostic services, provided they meet the necessary criteria. Its primary benefits encompass rapid results, reduced patient anxiety, and early detection of breast canceradvancements that significantly improve treatment outcomes. Diagnostic tests employed are generally safe and minimally invasive, with healthcare professionals dedicated to ensuring patient comfort throughout the process. Cost variations may arise depending on location, insurance coverage, and specific diagnostic requirements, for which patients could reach out to Apollo Cancer Centres for precise information. In case of breast cancer being detected, Apollo Cancer Centres program is equipped to guide patients toward personalized care, connecting them with skilled oncologists and specialists for a comprehensive treatment plan.” Dr Jayanti Thumsi- Lead Surgeon – Breast Oncology, Apollo Cancer Centre, Bangalore, said, “Our mission at Apollo Cancer Centres is to revolutionize cancer care through innovation and compassion. The 24 hours Breast Cancer Diagnosis Program is a significant stride in this direction. We understand the fear and anxiety that often accompanies a cancer diagnosis. With this program, we aim to reduce those burdens by providing women with rapid, precise diagnoses and a clear path towards tailored treatments on need basis. Every minute counts, and we are determined to make every moment count for the betterment of our patients.”
Dr. Manish Mattoo – Chief Executive Officer Karnataka Region, Apollo Hospitals said, “The launch of Indias First, Fastest & Precise Diagnosis program is a testament to our unwavering commitment to redefining cancer care. We believe that time is of the essence when it comes to breast cancer. Our goal is to provide hope and healing swiftly, offering women the timely and accurate diagnoses they deserve. With this program, we are not just reducing wait times; we are elevating patient outcomes, ensuring early intervention, and spreading the message of empowerment and resilience.” Dr Govindarajan M J Sr. Consultant – Radiology Apollo Cancer Centre, Bangalore, said,.”We recognise that an early diagnosis of breast cancer can be a turning point in a patient’s journey; achieving this quickly and accurately goes a long way in reducing patients’ anxiety and facilitates faster acceptance and timely treatment, which in turn improves the outcomes. The launch of India’s fastest & most precise breast cancer diagnosis program, represents our commitment to swift, precise diagnoses and tailored treatments. It’s not just about detecting cancer but providing empowerment, reassurance, and the best possible care to our patients when they need it the most.” Dr Aruna R Patil-Senior Consultant Radiologist, Apollo Cancer Centre, Bangalore, said, ” Our commitment to breast cancer diagnosis and care goes beyond just medical excellence; it extends to ensuring our patients are feeling empowered and supported. We understand that early diagnosis leads to better outcomes and improved quality of life. With our One-Day Cancer Diagnosis Program for Breast Cancer in Women, we aim to offer not only timely results but also a path to hope and recovery. This program allows us to combine our expertise with advanced diagnostic tools to deliver timely and accurate diagnosis. It is about providing the best care when our patients need it most. Dr Swarna Shivkumar- Senior Consultant Pathologist, Apollo Cancer Centre, BangaloreOur mission at Apollo Cancer Centres is to revolutionize cancer care through innovation and compassion. The One-Day Breast Cancer Diagnosis Program is a significant stride in this direction. We understand the fear and anxiety that often accompany a cancer diagnosis. With this program, we aim to reduce those burdens by providing women with rapid, precise diagnoses and a clear path toward tailored treatments on need basis. Every minute counts, and we are determined to make every moment count for the betterment of our patients.”
Aster Whitefield Hospital will offer Aster’s Centres of Excellence in Oncology, Cardiac Sciences,Neurosciences, Gastroenterology, Women & Child care and more bringing Internationalstandards of care to Bengaluru.
The hospital will be the first centre in India to offer Intra Operative Electron Radiation Therapy(IOERT) for precision treatment of Cancer
Bengaluru, October 31, 2023 – Aster DM Healthcare, one of the leading private healthcare service providers in GCC and India, today announced the expansion of its Aster Whitefield Hospital to becomea full-fledged, cutting-edge multi-super-specialty hospital located in the heart of Whitefield,Bangalore. The 506-bed state-of-the-art facility is set to revolutionize healthcare in the region with its comprehensive and specialized medical services. The expansion follows the success of Aster CMI and Aster RV Hospital, thus becoming the most trusted medical establishment in the region. Aster Whitefield will be Aster’s 3d multi-specialty hospital in Bengaluru and overall 19th hospital in India.The hospital was inaugurated by Chief Guest, Shri. Dinesh Gundu Rao, Hon’ble Minister for Healthand Family Welfare and Guest of Honour Shri U. T. Khader, Speaker of the Karnataka Legislative Assembly; Shri. Sharan prakash R Patil, Hon’ble Minister for Medical Education Government of Karnataka in the presence of Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare.
Other prominent dignitaries present on the occasion included:; Shri P. C. Mohan, Member of the LokSabha; Smt. Manjula Limbavali, Wife of Arvind Limbavali, Member of Legislative Assembly along with representatives from Aster DM Healthcare that is: Dr. Nitish Shetty, CEO, Aster DM Healthcare India;Prof. Dr. Somashekhar S P, Chairman – Medical Advisory Board, Aster DM Healthcare – GCC & India,Global Director – Aster International Institute of Oncology – GCC & India, Lead Consultant – Surgical &Gynaecological Oncology & Robotic Surgeon, HIPEC & PIPAC Super-specialist; and Mr. Ramesh Kumar, aCEO, Aster Hospitals, Bengaluru cluster.
The Aster Whitefield Hospital will cater to the diverse healthcare needs of the growing White field township. True to Aster’s brand promise of ‘We’ll treat you well’, the new hospital will offer patients world-class experience and enhance the city’s healthcare excellence. The hospital will house globally trained and experienced doctors with proven clinical excellence and support staff to offer exceptional patient care and medical outcomes. Aster Whitefield will feature Centres of Excellence in Oncology,Cardiac Sciences, Neurosciences, Gastroenterology, Integrated Liver Care, Multiorgan Transplantation, Urology & Nephrology, Advanced Robotics, Laparoscopic and conventional surgeries,Orthopaedics, Women’s Health and Child Adolescent Health.
The Aster Whitefield Multispecialty Hospital will be India’s first centre to offer Intra Operative Electron Radiation Therapy (IOERT) for precision treatment of Cancer. Other advanced technologies the hospital will offer include Hybrid Biplane Cath lab, 3D Mammogram, Digital PET CT, advanced LINAC,HIPEC/PIPEC Procedures, Full Room Digital Radiography and a Scalp Cooling System to prevent hair loss during chemotherapy. The hospital will also feature the 4th generation Da Vinci Robot for advanced surgeries in Oncology and Urology along with a state-of-the-art OT complex with 16Operating Theatres equipped with high-end medical equipments.
Speaking at the inauguration of the Aster Whitefield Hospital, Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare said, “We are proud to announce our 3rd state-of-theart hospital in Bengaluru and 19th hospital in India. The new hospital is in line with the group’s missionand commitment to our India business and growth plans to deliver seamless care by making health care accessible and affordable for our patients in India. Aster Whitefield exemplifies our dedication to delivering exceptional healthcare services to the burgeoning population of Whitefield. Our focus on specialties such as oncology, neurosciences and women & childcare reflects our dedication to addressing critical healthcare needs in the region. The 506-bed hospital will bring advanced medical at echnologies and expert care to the residents of Whitefield, addressing their diverse healthcare needs under one roof. With the Aster Whitefield launch, we reaffirm our commitment to India and will continue to deliver quality healthcare to our patients in India.”
Dr. Nitish Shetty, Group Chief Executive Officer, Aster DM Healthcare, India, added, “Aster Whitefield sets new benchmarks in healthcare excellence. We are dedicated to offering unparalleled services,integrating expertise with empathy, and ensuring our patients receive the best possible care. Driven by the increasing demand for high-tech healthcare services Aster Whitefield aims to provide world class medical care, making it the go-to destination for patients in need of specialized treatments. At Aster, we shall also work hard to stay ahead of the times to be among the firsts in the world to bring new, evidence-based, approved therapies and technology to our patients.”
Prof. Dr. Somashekhar S P, Chairman – Medical Advisory Board, Aster DM Healthcare – GCC & India,Global Director – Aster International Institute of Oncology – GCC & India, Lead Consultant – Surgical& Gynaecological Oncology & Robotic Surgeon, HIPEC & PIPAC Super-specialist said, “Today, as we unveil Aster Whitefield, we’re ushering in a new era of healthcare excellence. To provide the best of care for our Cancer patients, our multidisciplinary team at the Aster Institute of Oncology will integrate all clinical services including Surgical oncology, Medical oncology, Radiation oncology, Nuclear medicine therapy and Palliative oncology as part of the Disease Management Group (DMG) providing comprehensive prevention, screening, diagnosis, treatment, survivorship, and palliative end-of-lifecare services under one roof. With advanced medical technologies like Intra Operative Electron Radiation Therapy (IOERT) and the 4th Generation Da Vinci Robot, we are well-equipped to deliver precise and effective treatments. Our aim is to provide high quality international standard treatment at affordable cost with compassion and humane touch and be a one-stop solution to both diagnostics and therapeutic treatment – all under one roof.”
Beyond medical excellence, Aster Whitefield also offers a range of facilities for patients and their families, ensuring their comfort and well-being. As a tertiary multi-specialty hospital, Aster White fieldwill provide a holistic healthcare experience to patients as well as their caregivers.
Growing Bigger & Stronger Consistently NII at ₹ 823 crore up 24% Y-o-Y; PAT at ₹ 328 crore up 11% Y-o-Y Disbursed ₹ 5,749 crore / ₹ 11,033 crore in Q2FY24/H1FY24; Gross loan book up 27% Y-o-Y Asset quality continues to be healthy with GNPA/NNPA at 2.2%/0.09% & PAR at 3.7%; Deposits at ₹29,139 crore up 43% Y-o-Y; Retail TDs^ up 56% Y-o-Y
Bengaluru, 30 October, 2023: Ujjivan Small Finance Bank ltd. [BSE: 542904; NSE: UJJIVANSFB], today announced its financial performance for the quarter ended and half year ended September 30, 2023
Summary of Ujjivan Small Finance Bank Business Performance – Q2FY24 and H1FY24 Assets • Disbursements were at ₹ 5,749 crore/ ₹ 11,033 crore in Q2FY24/H1FY24 up 18%/20% Y-o-Y • Affordable Housing$ disbursed ₹ 541 crore/ ₹ 959 crore in Q2FY24/H1FY24 up 69%/58% Y-o-Y • Gross loan book at ₹26,574* crore up 27%/5% Y-o-Y/Q-o-Q Collection and Asset Quality • Continued traction on Collections with ~99% efficiency in Sep’23; NDA collection consistently at ~100% • Portfolio at risk* at 3.7% as of Sep’23 • GNPA* declined to 2.2% as of Sep’23 vs 2.4% as of Jun’23; NNPA* continues to be negligible at 0.09% as on Sep’23 • Total of ₹ 56 crore written-off in Q2FY24; Provision coverage ratio as on Sep’23 is 96%# Deposits • Deposits at ₹29,139 crore as of Sep’23 up by 43%/9% Y-o-Y/Q-o-Q • Retail TD^ grew 56%/8% Y-o-Y/Q-o-Q • CASA grew 28%/7% Y-o-Y/Q-o-Q; CASA ratio at 24.1% as on Sep’23 • Nationwide brand campaign and launch of value-add products yielding results Financials • Q2FY24 NII of ₹823 crores up 24% Y-o-Y; NIM at 8.8%* for Q2FY24 • Cost to Income ratio at 52.2% in Q2FY24 vs 52.5% for Q2FY23 • Q2FY24 PPoP at ₹483 crore up 26% Y-o-Y; PAT of ₹328 crore up 11% Y-o-Y Capital and Liquidity • Capital adequacy ratio at 25.2% with Tier-1 capital at 22.5% • Provisional LCR at 158% as on 30 Sep’23
Mr. Ittira Davis, MD & CEO, Ujjivan Small Finance Bank said, “Q2FY24 was yet another impressive quarter in terms of business performance. Business momentum continued its strong uptrend as seen in the previous quarters. Disbursements at ₹ 5,749 crore was strong registering a robust growth of 18% Y-o-Y and 9% Q-o-Q. Our secured book in Affordable Housing and FIG continues their strong performance. Further, our newer offerings like Gold loans and two-wheeler loans targeted to meet growing needs of our customer base is enhancing our product suite and will consequently aid growth. To provide further impetus to growth and brand awareness, we have introduced several initiatives during the quarter such as, launch of nation-wide brand campaign and value-add liability products targeting to enhance and deepen brand recall among our existing and potential stakeholders. Further we have also opened 39 new branches, taking our total branch count to 700. In H2 we will be adding ~45 more branches, this will include splitting of few branches to better manage the volumes. All these efforts have resulted in healthy growth of liabilities for our Bank. Our CASA has crossed ₹ 7,000 crore mark, growing by 28% Y-o-Y and 7% Q-o-Q. Further, our Retail TDs + CASA grew 44% Y-o-Y to ₹ 18,818 crore. Q2FY24 was yet another quarter where we marked ₹300 crore+ PAT. This was supported by our healthy NII growing by 24% Y-o-Y and 4% Q-o-Q. However, Cost of funds remained elevated in the current quarter as well, leading to NIM compression of 43 bps vs last quarter. We continue to stick to our guidance on loan and deposit book growth. Further we are also confident to maintain credit cost below 100 bps. Our strong focus on other initiatives such as ‘Hello Ujjivan’ is gaining acceptance among customers with 4.3 Lakhs downloads till date and total repayments of more than ₹ 40 crore in Q2FY24. ‘Digital FDs’ which was recently launched is also expected to bring business in the upcoming quarters. On merger with our promoter, as per order received from the Hon’ble NCLT, shareholder’s EGM is being convened on 3rd Nov’23 by the Bank as well as Ujjivan Financial Services. Once the merger is approved by the shareholders of both the companies, we will proceed with the remaining procedural and regulatory aspects. We expect the merger to be completed in Q4FY24.”
City Today News 
You must be logged in to post a comment.